MHRA — authorised 1 December 2005
- Marketing authorisation holder: Roche Registration Limited
- Status: approved
🇬🇧 Bevacizumab in United Kingdom
MHRA authorised Bevacizumab on 1 December 2005 · NICE has issued 16 UK HTA decisions
Marketing authorisation
Health technology assessment
16 decisions from NICE for Bevacizumab in United Kingdom.
NICE TA1136 — — Decision pending classification
- Indication assessed: metastatic colorectal cancer
NICE has recommended Bevacizumab for treating metastatic colorectal cancer. This decision was made based on a commercial arrangement. No restriction or condition was applied to the recommendation.
NICE TA1008 — ✓ Recommended
- Indication assessed: treating metastatic colorectal cancer after 2 systemic treatments
NICE recommended Bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments. This decision was made based on a commercial arrangement and a Patient Access Scheme. No restrictions were placed on the use of Bevacizumab.
NICE TA939 — ✓ Recommended
- Indication assessed: persistent, recurrent or metastatic cervical cancer
NICE recommended Bevacizumab for the treatment of persistent, recurrent or metastatic cervical cancer. This decision was made based on a commercial arrangement, indicating that the manufacturer agreed to a specific price or terms for the drug. There were no restrictions or conditions placed on the use of Bevacizumab for this indication.
NICE TA284 — ✗ Not recommended
- Indication assessed: first-line treatment of advanced ovarian cancer
NICE did not recommend Bevacizumab for the first-line treatment of advanced ovarian cancer. This decision was made without a reported cost-effectiveness analysis or patient access scheme. No commercial arrangement or restriction was mentioned in the decision.
NICE TA263 — ✗ Not recommended
- Indication assessed: the first-line treatment of metastatic breast cancer
NICE did not recommend Bevacizumab for the first-line treatment of metastatic breast cancer. This decision was made without a reported cost-effectiveness analysis, as the ICER was not provided. No patient access scheme or commercial arrangement was considered.
NICE TA178 — — Decision pending classification
- Indication assessed: the treatment of advanced and/or metastatic renal cell carcinoma
NICE made an unclassified decision on Bevacizumab for the treatment of advanced and/or metastatic renal cell carcinoma. The decision was based on the drug's clinical effectiveness and cost. No Patient Access Scheme or commercial arrangement was in place.
NICE TA148 — — Appraisal terminated
- Indication assessed: the treatment of non-small-cell lung cancer (terminated appraisal)
NICE made a decision to terminate the appraisal of Bevacizumab for the treatment of non-small-cell lung cancer. This decision means that the appraisal process has been stopped. The decision was made without a recommendation on the cost-effectiveness of Bevacizumab, as the appraisal was terminated.
NICE TA1022 — ✓ Recommended
- Indication assessed: treating wet age-related macular degeneration
NICE recommended Bevacizumab for treating wet age-related macular degeneration. This decision was made based on a commercial arrangement and a Patient Access Scheme, which suggests that the drug's price was negotiated to be within the National Health Service's budget. There were no restrictions placed on the use of Bevacizumab for this indication.
NICE TA946 — ✓ Recommended
- Indication assessed: maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
NICE recommended Bevacizumab for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. This decision was made based on a commercial arrangement, indicating that the manufacturer agreed to a specific price or terms. There were no restrictions or conditions placed on the use of Bevacizumab for this indication.
NICE TA666 — ✓ Recommended
- Indication assessed: treating advanced or unresectable hepatocellular carcinoma
NICE recommended Bevacizumab for treating advanced or unresectable hepatocellular carcinoma. This decision was made based on a commercial arrangement and a Patient Access Scheme. No restrictions were placed on the use of Bevacizumab for this indication.
NICE TA560 — — Appraisal terminated
- Indication assessed: treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
NICE made a decision to terminate the appraisal of Bevacizumab for treating the first recurrence of platinum-sensitive advanced ovarian cancer. This decision means that NICE will not make a recommendation on the use of Bevacizumab for this indication. The decision to terminate the appraisal was made without a recommendation on the cost-effectiveness of Bevacizumab, as no cost-effectiveness analysis was reported.
NICE TA436 — — Appraisal terminated
- Indication assessed: treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
NICE made a decision to terminate the appraisal of Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer. This decision means that NICE will not make a recommendation on the use of Bevacizumab for this specific indication. The decision was made without a cost-effectiveness assessment, as the Patient Access Scheme and Commercial arrangement fields were both marked as False.
NICE TA353 — — Appraisal terminated
- Indication assessed: treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
NICE made a decision to terminate the appraisal of Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. This decision means that NICE will not make a recommendation on the use of Bevacizumab for this indication. The decision to terminate the appraisal was made without a cost-effectiveness assessment, as no ICER was reported.
NICE TA285 — ✗ Not recommended
- Indication assessed: treating the first recurrence of platinum-sensitive advanced ovarian cancer
NICE made a decision not to recommend Bevacizumab for treating the first recurrence of platinum-sensitive advanced ovarian cancer. This decision was made without a reported cost-effectiveness analysis. No patient access scheme or commercial arrangement was considered.
NICE TA242 — ✗ Not recommended
- Indication assessed: the treatment of metastatic colorectal cancer after first-line chemotherapy
NICE did not recommend Bevacizumab for the treatment of metastatic colorectal cancer after first-line chemotherapy. This decision was made without a reported cost-effectiveness analysis. No patient access scheme or commercial arrangement was considered.
NICE TA214 — ✗ Not recommended
- Indication assessed: the first-line treatment of metastatic breast cancer
NICE made a decision not to recommend Bevacizumab for the first-line treatment of metastatic breast cancer. This decision was made without a reported cost-effectiveness analysis or a patient access scheme. No commercial arrangement was considered.
Bevacizumab in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Bevacizumab approved in United Kingdom?
Yes. MHRA authorised it on 1 December 2005.
Who is the marketing authorisation holder for Bevacizumab in United Kingdom?
Roche Registration Limited holds the UK marketing authorisation.
Has Bevacizumab been assessed by UK health technology agencies?
Yes — 16 UK HTA decisions on record from NICE.